
About
Aquestive is a pharmaceutical company dedicated to advancing medicines that significantly improve patients' lives through innovative science and delivery technologies. Utilizing proprietary technologies such as PharmFilm® and AdrenaVerse™, the company focuses on developing patient-friendly alternatives to traditional therapies, including investigational treatments for anaphylaxis and alopecia areata. Founded in 2005, Aquestive has built a robust drug delivery platform and has expertise across the entire product lifecycle, from formulation to commercialization, with several FDA-approved products and a commitment to ethical conduct and environmental stewardship.
Verified company data
- Cash position
- $110.7 million
- Shares outstanding
- 98,871,369
- Projects
Anaphylm™ (dibutepinephrine) sublingual film
Potential Indication
Type 1 allergic reactions, including anaphylaxis
Pre-ClinicalPhase 1Phase 2Phase 3
An oral film formulation using Aquestive’s novel prodrug of epinephrine for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.
Learn moreAQST-108 (epinephrine) topical gel
Potential Indication
(multiple potential indications)
Pre-ClinicalPhase 1Phase 2Phase 3Libervant® (diazepam) buccal film
Potential Indication
Acute repetitive seizures / cluster seizures
Pre-ClinicalPhase 1Phase 2Phase 3
An oral film formulation of diazepam being developed as a rescue therapy for intermittent, stereotypic episodes of frequent seizure activity (also known as seizure clusters) in patients with epilepsy.
Learn more- Leadership
Daniel Barber (Chief Executive Officer, President and Director, Appointed CEO in May 2022 after serving as COO since May 2019. Joined Aquestive in 2007 and has played a key role in its growth, overseeing the launch of the company's first two FDA approved products.), Kristin Sokol, MD, MS, MPH, FACAAI, FAAAAI (not discovered), Wanda Phipatanakul, MD, MS (not discovered), S. Shahzad Mustafa, MD (not discovered), Douglas P. Mack, MSc, MD, FRCPC, FCSACI (not discovered), Scott Commins, MD, PhD (not discovered), Christina E. Ciaccio, MD, MSc (not discovered), Aikaterini Anagnostou, MD, PhD (not discovered), Rich Daly (not discovered), Thomas A. Zalewski (not discovered), John Oppenheimer, M.D. (not discovered)
Verified data last updated:
Recent filings
- Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference · Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference (QuoteMedia 7050061246931837)
- Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting · Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting (QuoteMedia 8387293086946774)
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET · Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET (QuoteMedia 8184140091530906)
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly · Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly (QuoteMedia 8495619531637068)
- Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET · Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET (QuoteMedia 6781725694425870)
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism · Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (QuoteMedia 8874304015152574)
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree · Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree (QuoteMedia 5862147043212312)
- Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET · Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET (QuoteMedia 7087728595130433)
Investor FAQ
Aquestive is scheduled to present at the Jefferies Global Healthcare Conference, and it has announced data presentations at the 2026 ACAAI Annual Meeting. The company has also announced it will report third quarter 2026 financial results and recent business highlights on November 3, 2026, with a conference call on November 4, 2026 at 8:00 a.m. ET. Specific regulatory dates or clinical readout timelines for Anaphylm™, AQST-108, and Libervant® are not disclosed in the available documents.
- Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference ·
- Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting ·
- Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET ·
The most recent announcements include the Jefferies Global Healthcare Conference presentation (2026-11-09) and the ACAAI Annual Meeting data presentation (2026-11-05). Earlier in 2026, Aquestive appointed Richard Daly to its Board of Directors on 2026-09-29 and completed a $150 Million debt refinancing with Oaktree on 2026-05-12. The company also reported second quarter 2026 financial results and business highlights on August 11, 2026, with a conference call on August 12, 2026.
- Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference ·
- Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting ·
- Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly ·
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree ·
- Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET ·
Answers last refreshed: